Medical/Pharmaceuticals
Sciwind Biosciences Announces Ecnoglutide Injection Approved by China's National Medical Products Administration (NMPA) for Chronic Weight Management
HANGZHOU, China, March 6, 2026 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind"), a biopharmaceutical company focused on the discovery and development of innovative therapies for metabolic diseases, announced today that China's National Medical Products Administration (NMPA) has ...
2026-03-06 14:39
3884
Ceretone Launches in Australia with Flagship Core One Pro, Revolutionizing Access to Premium Hearing Solutions
MELBOURNE, Australia, March 6, 2026 /PRNewswire/ -- Ceretone
2026-03-06 08:00
2581
The world's largest brain research prize awarded for groundbreaking discoveries on how we sense touch and pain
The Brain Prize 2026 is awarded to Professors David Ginty (US) and Patrik Ernfors (Sweden) for their pioneering discoveries on how the nervous system detects and processes touch and pain. Their work has rewritten textbooks and opened new avenues for the development of targeted treatments for cond...
2026-03-05 23:00
Datasea Accelerates Global Commercialization of Acoustic + AI Health Care Robots, Expanding Scalable Applications in China and International Markets
Initial Technical Service Revenue Achieved as the Company Advances Global Deployment and Chain Expansion with Strategic Partner BEIJING, March 5, 2026 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), a technology company specializing in acoustic high-tech innovation and ...
2026-03-05 22:30
3025
Cerecin Announces TEDx Talk by CEO Dr. Charles Stacey is Now Available Online
Titled "The Potential of Fasting and Diet in the Future of Medicine" Highlighting the Potential of Ketones - from Fasting, the Ketogenic diet and Pharmaceuticals - to Address Neurological Disease and Improve Brain Health DENVER, Colo., March 5, 2026 /PRNewswire/ -- Cerecin Inc., a clinical-stage ...
2026-03-05 22:28
2660
Cadonilimab Achieves 100% 24-Month OS in Complete Responders in R/M Cervical Cancer Based on Long-Term Phase II Results
HONG KONG, March 4, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the latest long-term survival analysis data from the China pivotal registrational Phase II study (COMPASSION-03/AK104-201) of cadonilimab as a monotherapy for patients with recurrent or metasta...
2026-03-05 10:26
5226
Terumo Blood and Cell Technologies introduces APAC C> Ecosystem Blueprint
A collaborative integration model to enable practical, scalable cell and gene therapy delivery. SINGAPORE, March 5, 2026 /PRNewswire/ -- Terumo Blood and Cell Technologies (Terumo BCT) today announced the launch of its new C> Ecosystem Blueprint — a practical, collaborative approach designed t...
2026-03-05 10:10
3506
Empowering the SBMA Community: AnnJi Highlights Patient & Family Forum and Shares AJ201 Scientific Advancement at the 2026 KDA Conference
TAIPEI, March 4, 2026 /PRNewswire/ -- AnnJi Pharmaceutical Co., Ltd. (AnnJi, TWSE: 7754) announced its participation in the 2026 International Patient and Scientific Conference hosted by the Kennedy's Disease Association (KDA). Held between February 27 and March 2, the conference served as a prem...
2026-03-05 09:47
4337
Lunit to Be Featured in 21 AI Imaging Studies on Breast Cancer and Lung Disease at ECR 2026
* 13 oral presentations included, reaffirming the clinical value of AI-based medical image analysis * Highlighting key topics such as early risk stratification based on AI abnormality scores and interval cancer classification SEOUL, South Korea, March 4, 2026 /PRNewswire/ -- Lunit (KRX:32813)...
2026-03-04 22:00
5233
Akeso and INOVIO Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)
* Collaboration will evaluate Akeso's cadonilimab in combination with INOVIO's INO-5412 (INO-5401 plus INO-9012) as a potential treatment for glioblastoma (GBM), the most common and aggressive form of brain cancer * Novel combination therapy will be studied as part of the Phase II adaptive pl...
2026-03-04 21:52
5481
MGI Tech Announces Acquisition of STOmics and CycloneSEQ to Deliver Integrated Long-Read, Short-Read and Spatial Omics Solutions
SHENZHEN, China, March 4, 2026 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company dedicated to developing core tools and technologies that drive innovation in the life sciences, today announced the acquisition of STOmics and CycloneSEQ. It marks a significant milestone in MGI's "SEQALL+GLI+Omi...
2026-03-04 11:58
4541
Gene Solutions Announces Strategic Entry into Türkiye with Robust Real-World Evidence at the 2nd International Hereditary Cancers Congress 2026
In Partnership with ATC Genomics, the Company Presented One of Asia's Largest Real-World Datasets (n=12,281) for AI-Powered Multi-Cancer Early Detection (MCED) and Showcased its Clinically Validated ctDNA-Powered Oncology Portfolio Across the Full Cancer Continuum for High-Risk and Hereditary Pop...
2026-03-04 10:00
6606
Advancing Influenza Vaccine Development: Sino Biological Launches Antigens for the 2026-2027 Northern Hemisphere Influenza Vaccine Strains
HOUSTON, March 3, 2026 /PRNewswire/ -- The World Health Organization (WHO) has announced its recommendations for the 2026–2027 Northern Hemisphere influenza vaccine composition, highlighting the continued spread of A(H3N2) subclade K and emerging B/Victoria lineage strains. In rapid response, Sin...
2026-03-04 09:53
5097
PROTECTHEALTH STRENGTHENS GOVERNANCE AND SERVICE CONTINUITY WITH ISO 22301 BCMS CERTIFICATION
CYBERJAYA, Malaysia, March 4, 2026 /PRNewswire/ -- ProtectHealth Corporation Sdn. Bhd. has reinforced its role as a key government agency and strategic purchaser of healthcare services with the successful attainment of the ISO 22301:2019/AMD1:2024 Business Continuity Management System (BCMS) Cert...
2026-03-04 08:44
4014
Antengene and UCB Enter Global License Agreement for ATG-201, a CD19/CD3 Bispecific T-Cell Engager for Autoimmune Diseases
* Antengene grants UCB worldwide exclusive rights to develop, manufacture and commercialize ATG-201, a CD19/CD3 bispecific T-cell engager (TCE) antibody, targeting B cell-related autoimmune diseases. * Antengene will receive USD 80 million of upfront and near-term milestone payments, and is e...
2026-03-04 06:00
4938
iClever Joins Forces with Renowned Audiologist Kellsie Busho to Champion Children's Hearing Health on World Hearing Day 2026
NEWARK, N.J., March 3, 2026 /PRNewswire/ -- As digital learning and personal audio devices become central to childhood, experts warn of rising risks of preventable hearing damage. Marking World Hearing Day, iClever, the No.1 selling kids' headphone brand in the U.S. online market, today announced...
2026-03-04 00:08
5632
HiRO Leads Cross‑Border Dialogue at JPM, Offering Insights for Biotechs Seeking Asian Investment
SOMERSET, N.J., March 3, 2026 /PRNewswire/ -- Harvest Integrated Research Organization (HiRO), a global contract research organization specializing in strategic planning for clinical development and cross‑border clinical trial solutions and services, concluded a successful presence at the 44th An...
2026-03-03 22:30
3830
Insilico Medicine and Liquid AI Announce Strategic Partnership Delivering Lightweight Scientific Foundation Models for Drug Discovery
Single 2.6B-parameter model achieves state-of-the-art performance across drug discovery benchmarks while running entirely on private pharmaceutical infrastructure CAMBRIDGE, Mass., March 3, 2026 /PRNewswire/ -- Insilico Medicine and Liquid AI today announced a partnership that creates lightweigh...
2026-03-03 22:25
5268
REPROCELL Launches GMP Master Cell Bank Manufacturing for Clinical iPSCs
Integrated Workflow Including Clinical Seed Production and StemEdit Gene Editing Services BELTSVILLE, Md., March 3, 2026 /PRNewswire/ -- REPROCELL (TYO: 4978) today announced the launch of its US FDA compliant Good Manufacturing Practice (GMP) Master Cell Bank (MCB) manufacturing service for hum...
2026-03-03 22:00
3994
Senhwa Biosciences Signs Major Strategic MOU with Y Combinator-Backed AI Biotech Company CellType to Accelerate the Evolution of CX-4945 into Version 2.0 and Reshape the Global Immunotherapy Landscape
TAIPEI and SAN DIEGO, March 3, 2026 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical stage company focusing on development of first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced the signing of a major strategic Memorandum of Understa...
2026-03-03 15:51
4654
Week's Top Stories
Most Reposted
Tetra Pak Opens Product Development Centre in Thailand, Unlocking A World of Possibilities for Food and Beverage Innovators Across Asia Pacific
[Picked up by 313 media titles]
2026-03-27 11:15
Visa Working Capital Index: Asia Pacific CFOs Call for Flexible, Digital Finance Solutions
[Picked up by 309 media titles]
2026-03-24 14:00Indonesia's P2P Lending Grows 25%, JULO Strengthens Credit Quality
[Picked up by 300 media titles]
2026-03-26 18:18
ART CENTRAL COMMENCES DISCOVERY-LED ELEVENTH EDITION
[Picked up by 277 media titles]
2026-03-25 16:51
RoboSense Beat Expectations, Achieved First-Ever Quarterly Profit on Strong Robotics Growth
[Picked up by 269 media titles]
2026-03-25 22:51
Most Read
FiEE, Inc. Announces Fourth Quarter and Full-Year 2025 Financial Results
2026-03-21 04:05
7968
U Power Limited Announces Closing of $6.0 Million Public Offering
2026-03-21 02:40
7431